Lineage Cell Therapeutics Inc. (AMEX: LCTX) is 9.66% higher on its value in year-to-date trading and has touched a low of $0.58 and a high of $2.01 in the current 52-week trading range. The LCTX stock was last observed hovering at around $1.76 in the last trading session, with the day’s gains setting it 0.17% off its average median price target of $4.00 for the next 12 months. It is also 72.43% off the consensus price target high of $7.00 offered by 6 analysts, but current levels are 35.67% higher than the price target low of $3.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Currently trading at $1.93, the stock is 12.57% and 31.24% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.83 million and changing 9.66% at the moment leaves the stock 84.87% off its SMA200. LCTX registered 132.36% gain for a year compared to 6-month gain of 144.21%. The firm has a 50-day simple moving average (SMA 50) of $1.5853 and a 200-day simple moving average (SMA200) of $1.1286.
The stock witnessed a 26.97% loss in the last 1 month and extending the period to 3 months gives it a 101.04%, and is 9.66% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.56% over the week and 7.84% over the month.
Lineage Cell Therapeutics Inc. (LCTX) has around 55 employees, a market worth around $286.22M and $2.70M in sales. Distance from 52-week low is 232.70% and -3.98% from its 52-week high. The company has generated returns on investments over the last 12 months (-27.80%).
Lineage Cell Therapeutics Inc. (LCTX) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Lineage Cell Therapeutics Inc. (LCTX) is a “Buy”. 6 analysts offering their recommendations for the stock have an average rating of 2.20, where 1 rate it as a Hold and 0 think it is a “Overweight”. 5 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Lineage Cell Therapeutics Inc. is expected to release its quarterly report on 05/13/2021 and quarterly earnings per share for the current quarter are estimated at -$0.05 with sales reaching $820k over the same period.The EPS is expected to grow by 77.80% this year, but quarterly earnings will post -36.60% year-over-year. Quarterly sales are estimated to shrink -33.90% in year-over-year returns.
Lineage Cell Therapeutics Inc. (LCTX) Top Institutional Holders
88 institutions hold shares in Lineage Cell Therapeutics Inc. (LCTX), with 7.57M shares held by insiders accounting for 5.05% while institutional investors hold 37.67% of the company’s shares. The shares outstanding are 149.97M, and float is at 142.41M with Short Float at 4.38%. Institutions hold 35.77% of the Float.
The top institutional shareholder in the company is Broadwood Capital, Inc. with over 34.01 million shares valued at $31.85 million. The investor’s holdings represent 22.67% of the LCTX Shares outstanding. As of Sep 29, 2020, the second largest holder is Vanguard Group, Inc. (The) with 5.23 million shares valued at $4.9 million to account for 3.49% of the shares outstanding. The other top investors are Defender Capital, LLC which holds 5.05 million shares representing 3.37% and valued at over $4.73 million, while Prescott General Partners LLC holds 1.23% of the shares totaling 1.85 million with a market value of $1.73 million.